Freek W A Verheugt
Overview
Explore the profile of Freek W A Verheugt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
301
Citations
8399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Himmelreich J, Virdone S, Camm A, Pieper K, Harskamp R, Verheugt F, et al.
Open Heart
. 2025 Jan;
12(1.
PMID: 39832940
Aims: This study aimed to determine the robustness, reproducibility and representativeness of the landmark Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (AF) (ARISTOTLE) and Rivaroxaban...
2.
van Campen C, Verheugt F, Rowe P, Visser F
Healthcare (Basel)
. 2025 Jan;
12(24.
PMID: 39765993
Introduction: Orthostatic intolerance is highly prevalent in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and is caused by an abnormal reduction in cerebral blood flow (CBF). In healthy controls (HCs),...
3.
Clinical Outcomes in Older Patients with Atrial Fibrillation: Insights from the GARFIELD-AF Registry
Goldhaber S, Bassand J, Camm A, Virdone S, Pieper K, Cools F, et al.
Am J Med
. 2023 Nov;
137(2):128-136.e13.
PMID: 37918777
Background: Oral anticoagulants (OAC) are underutilized in older patients with atrial fibrillation, despite proven clinical benefits. Our objective was to investigate baseline characteristics, treatment patterns, and impact of anticoagulation upon...
4.
Verheugt F, Fox K, Virdone S, Ambrosio G, Gersh B, Haas S, et al.
Am J Med
. 2023 Sep;
136(12):1187-1195.e15.
PMID: 37704071
Background: Many patients with atrial fibrillation suffer from comorbid vascular disease. The comparative efficacy and safety of different types of oral anticoagulation (OAC) in this patient group have not been...
5.
van Campen C, Rowe P, Verheugt F, Visser F
Physiol Rep
. 2023 Sep;
11(17):e15639.
PMID: 37688420
Brain perfusion is sensitive to changes in CO levels (CO reactivity). Previously, we showed a pathological cerebral blood flow (CBF) reduction in the majority of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)...
6.
Bassand J, Virdone S, Camm A, Fox K, Goldhaber S, Goto S, et al.
Diabetes Obes Metab
. 2023 Jul;
25(10):3040-3053.
PMID: 37435777
Aims: This study aims to describe both management and prognosis of patients with diabetes mellitus (DM) and newly diagnosed atrial fibrillation (AF), overall as well as by antidiabetic treatment, and...
7.
van Campen C, Verheugt F, Rowe P, Visser F
IBRO Neurosci Rep
. 2023 Jun;
15:1-10.
PMID: 37303862
Background: Orthostatic intolerance (OI) is a core diagnostic criterion in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The majority of ME/CFS patients have no evidence of hypotension or postural orthostatic tachycardia syndrome...
8.
Camm A, Steffel J, Virdone S, Bassand J, Fox K, Goldhaber S, et al.
Eur Heart J Open
. 2023 Jun;
3(3):oead051.
PMID: 37293139
Aims: This study aimed to identify relationships in recently diagnosed atrial fibrillation (AF) patients with respect to anticoagulation status, use of guideline-directed medical therapy (GDMT) for comorbid cardiovascular conditions (co-GDMT),...
9.
10.
Mantovani L, Cozzolino P, Ferrara P, Virdone S, Camm A, Verheugt F, et al.
Healthcare (Basel)
. 2023 Mar;
11(5).
PMID: 36900643
The management of atrial fibrillation (AF), the most common sustained arrhythmia, impacts healthcare resource utilization (HCRU). This study aims to estimate global resource use in AF patients, using the GARFIELD-AF...